Search Results

Bexion Pharmaceuticals, Inc. announced that the Company will present at the 2024 Biotechnology Innovation Organization International Convention taking place June 3-6, 2024, in San Diego, California.

Bexion Pharmaceuticals, Inc. today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.

Bexion Pharmaceuticals, Inc. announced today that the Company presented a poster on BXQ-350 during the American Association for Cancer Research (AACR) Annual Meeting 2024 which took place April 5-10, 2024, in San Diego, CA.

Bexion Pharmaceuticals, Inc. today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA.

Bexion Pharmaceuticals, Inc. announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week. Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.

Bexion Pharmaceuticals, Inc. announced today that the Company will participate in the 2023 Cantor Global Healthcare Conference.

Bexion Pharmaceuticals, Inc. announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum.

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Dr. Catherine Pearce, DHSc, MBA, to the Company’s Board of Directors, effective October 1, 2023.

Bexion Pharmaceuticals, Inc. announced that Bexion Pharmaceuticals will be presenting at the Needham Healthcare Conference.